Drug intelligence / Profile preview

TNX-4100

Development stage: Preclinical
Lead developer: Tonix Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TNX-4100 consists of murine monoclonal antibodies and their humanized counterparts generated from mice immunized with the SARS-CoV-2 spike protein. The antibodies are being developed as candidate therapeutics for the treatment and prophylaxis of COVID-19 and are notable for their potential to neutralize a broader spectrum of SARS-CoV-2 variants, given the diversity of mouse antibody repertoires compared to humans. These antibodies are being developed in collaboration between Tonix Pharmaceuticals and Columbia University, leveraging internal biologics manufacturing capabilities. As of October 2025, no clinical trial results or development phases have been reported for TNX-4100.[3][7]

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on TNX-4100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNX-4100.

Explore the full profile